Neurofibromatosis Therapeutics Program: Program Development, Tumor Treatment, and Side Effect Management (215)

9:45 am – 10:50 am Friday, September 16
The advanced practice provider is instrumental in designing, developing, and growing a program to treat tumors associated with Neurofibromatosis (NF) Type 1 and 2. Both NF1 and NF2 are autosomal dominant genetic disorders associated with the growth of both benign and malignant tumors of the peripheral and central nervous system. In the last two years selumetinib, a MEK inhibitor, gained FDA approval for treatment of plexiform neurofibromas in the children with NF.
With new treatment available the patient care load increased significantly. As with all MEK inhibitors, the side effect management is extensive and labor intense. A tertiary care hospital formed a formal program, the Neurofibromatosis Therapeutics Program, within the Center for Cancer and Blood Disorders. The aim of the program is to work in a multidisciplinary setting to care for patients with plexiform neurofibromas, meningiomas, low grade gliomas, high grade gliomas, and malignant peripheral nerve sheath tumors. The treatment and side effect management of these tumors will be discussed, along with the program development pearls that have been gleaned.
Molly Hemenway DNP MS RN CPNP-AC/PC
CNE Hours: